Theravance Biopharma (TBPH) Competitors $11.22 +0.32 (+2.94%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$14.94 +3.72 (+33.11%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. BEAM, ARWR, TWST, HRMY, IDYA, IRON, MESO, CNTA, VCEL, and CGONShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Beam Therapeutics (BEAM), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Mesoblast (MESO), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Theravance Biopharma vs. Its Competitors Beam Therapeutics Arrowhead Pharmaceuticals Twist Bioscience Harmony Biosciences IDEAYA Biosciences Disc Medicine Mesoblast Centessa Pharmaceuticals Vericel CG Oncology Beam Therapeutics (NASDAQ:BEAM) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Is BEAM or TBPH more profitable? Theravance Biopharma has a net margin of -89.38% compared to Beam Therapeutics' net margin of -609.24%. Theravance Biopharma's return on equity of -32.37% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-609.24% -44.24% -30.97% Theravance Biopharma -89.38%-32.37%-16.48% Does the media favor BEAM or TBPH? In the previous week, Beam Therapeutics had 8 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Beam Therapeutics and 0 mentions for Theravance Biopharma. Beam Therapeutics' average media sentiment score of 0.63 beat Theravance Biopharma's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Beam Therapeutics Positive Theravance Biopharma Neutral Which has better earnings & valuation, BEAM or TBPH? Theravance Biopharma has higher revenue and earnings than Beam Therapeutics. Theravance Biopharma is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M30.27-$376.74M-$4.61-4.15Theravance Biopharma$64.38M8.71-$56.42M-$1.18-9.51 Which has more volatility and risk, BEAM or TBPH? Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Do insiders & institutionals have more ownership in BEAM or TBPH? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate BEAM or TBPH? Beam Therapeutics currently has a consensus price target of $48.75, indicating a potential upside of 154.97%. Theravance Biopharma has a consensus price target of $16.60, indicating a potential upside of 47.95%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryBeam Therapeutics beats Theravance Biopharma on 10 of the 17 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$545.01M$2.50B$5.51B$9.35BDividend YieldN/A1.78%4.74%4.16%P/E Ratio-9.519.0129.1724.41Price / Sales8.71654.27435.4290.24Price / CashN/A22.2824.4827.20Price / Book3.145.008.495.77Net Income-$56.42M$31.61M$3.24B$264.99M7 Day Performance1.72%-2.08%0.63%-0.68%1 Month Performance0.31%5.68%7.95%7.08%1 Year Performance17.00%5.21%30.47%23.80% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma2.3063 of 5 stars$11.22+2.9%$16.60+48.0%+16.4%$545.01M$64.38M-9.51110Upcoming EarningsBEAMBeam Therapeutics2.7628 of 5 stars$20.83-4.1%$48.75+134.0%-30.3%$2.18B$63.52M-4.52510ARWRArrowhead Pharmaceuticals3.8324 of 5 stars$16.20+2.9%$43.71+169.8%-37.2%$2.17B$3.55M-11.57400Upcoming EarningsTWSTTwist Bioscience3.443 of 5 stars$36.53+1.5%$50.40+38.0%-29.7%$2.16B$312.97M-11.24990News CoverageGap DownHRMYHarmony Biosciences4.7465 of 5 stars$35.76-4.7%$51.00+42.6%+9.7%$2.15B$744.85M13.65200Positive NewsIDYAIDEAYA Biosciences4.2015 of 5 stars$25.02+2.1%$48.09+92.2%-37.6%$2.15B$7M-6.9780High Trading VolumeIRONDisc Medicine3.4085 of 5 stars$59.48-1.9%$95.73+60.9%+39.6%$2.10BN/A-15.1730Upcoming EarningsMESOMesoblast0.7658 of 5 stars$15.93-2.6%$18.00+13.0%+144.1%$2.09B$5.90M0.0080CNTACentessa Pharmaceuticals3.0455 of 5 stars$15.20-1.4%$28.10+84.9%+59.7%$2.06B$6.85M-8.40200Upcoming EarningsVCELVericel2.4371 of 5 stars$41.45+3.3%$61.14+47.5%-21.1%$2.02B$237.22M1,382.13300Earnings ReportShort Interest ↑Analyst RevisionCGONCG Oncology1.9013 of 5 stars$25.86-0.9%$55.30+113.8%-20.0%$1.99B$1.14M-17.1361 Related Companies and Tools Related Companies BEAM Alternatives ARWR Alternatives TWST Alternatives HRMY Alternatives IDYA Alternatives IRON Alternatives MESO Alternatives CNTA Alternatives VCEL Alternatives CGON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
